Blog
Another Promising Treatment for Alzheimer’s disease
Last week, Eli Lilly and Company announced that it has applied for U.S Food and Drug Administration (FDA) approval for its Alzheimer’s treatment, donanemab, and expects an FDA decision by the end of 2023. [View More]
FDA Grants Full Approval to Leqembi® and Medicare Expands Coverage
On Thursday, July 6, Leqembi® (lecanemab – irmb), became the first beta-amyloid targeting medication for the treatment of Alzheimer’s disease to receive full approval from the U.S. Food and Drug Administration (FDA). The drug, from pharmaceutical [View More]
Spring Gala Celebrating Connections
Spring Gala Celebrating Connections At the Gala on April 27, Alzheimer’s New Jersey was pleased to recognize two leaders in the New Jersey fight against Alzheimer’s disease. Russell Rothman and Heather Rae Stafford [View More]
FDA Approves Leqembi™
On Friday, January 6, the US Food and Drug Administration gave accelerated approval to Leqembi™ (lecanemab – irmb), a drug developed by Eisai in partnership with Biogen, for the treatment of Alzheimer’s disease. The drug [View More]
Embracing Your “Land of Hope and Dreams”
I’ve been a fan of Bruce Springsteen’s music for as long as I can remember. His “stories” have spoken to me in different ways during different periods of my life. Perhaps, that comes from [View More]
Lecanemab Clinical Trial Data
Recently released data from Eisai’s Phase 3 clinical trial of lecanemab shows that the drug slowed the rate of cognitive decline by 27% as compared to the placebo group in an 18-month study of participants [View More]
